- Details
- Phillip Koo interviews Wolfgang Fendler about advancements in PSMA PET imaging and its prognostic capabilities. Dr. Fendler highlights that the PROMISE criteria, developed for standardized PSMA PET reporting, now show significant prognostic value in predicting overall survival in prostate cancer across all stages. His team’s research demonstrates that metrics like total tumor volume and average PS...
|
- Details
- Michael Morris shares insights into his presentation on a novel hK2-targeting antibody radioconjugate, JNJ-6420, which uses an actinium radioisotope. Dr. Morris explains that hK2, akin to PSA, binds to prostate cancer cell membranes, making it an ideal target for this radioligand therapy. Unlike existing beta emitters, this alpha-emitting treatment delivers intense, localized radiation, promising...
|
- Details
- Alicia Morgans interviews Samuel Denmeade about the TRANSFORMER trial and Bipolar Androgen Therapy (BAT) for prostate cancer. Dr. Denmeade explains that the trial, involving 200 patients, compared high-dose testosterone therapy to enzalutamide in treating hormone-resistant prostate cancer. Surprisingly, both treatments showed similar efficacy, with each offering about a six-month response duration...
|
- Details
- Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...
|
- Details
- PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups. Here we re...
|
- Details
- Andrea Miyahira hosts Tanya Stoyanova to discuss her study, published in Cell Reports Medicine, on UCHL1 as a potential biomarker and therapeutic target for neuroendocrine carcinomas, including neuroendocrine prostate cancer. Dr. Stoyanova explains that UCHL1, which has dual functions in protein stability, is highly expressed in neuroendocrine tumors and not in non-neuroendocrine ones. The study f...
|
- Details
- Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...
|
- Details
- Alicia Morgans speaks with Neha Vapiwala about advancements in radiotherapy for high-risk and locally advanced prostate cancer. Dr. Vapiwala highlights the importance of dose escalation in improving survival and explains the benefits of moderate and ultra-hypofractionation, including the use of stereotactic body radiotherapy (SBRT). She emphasizes that while SBRT can safely deliver higher doses of...
|
- Details
- Alicia Morgans speaks with Mary-Ellen Taplin about strategies for managing metastatic hormone-sensitive prostate cancer (mHSPC) patients who do not achieve optimal PSA declines. Dr. Taplin emphasizes that an unfavorable PSA decline is not synonymous with progression and highlights the prognostic value of achieving a PSA nadir below 0.2. She discusses data from various trials, such as SWOG 9346, CH...
|
- Details
- Alicia Morgans interviews Sandy Srinivas about her presentation on treating the primary tumor in synchronous high-volume metastatic hormone-sensitive prostate cancer. Dr. Srinivas reviews key trials such as HORRAD and STAMPEDE, which indicate that radiating the primary tumor may benefit low-volume patients but not those with high-volume disease. She highlights the PEACE-1 trial, which found no sur...
|
